TECENTRIQ® (atezolizumab) and new safety concern of immune-related nephritis

Roche Singapore Pte Ltd would like to inform healthcare professionals of the new safety concern of immune-related nephritis associated with Tecentriq^® (atezolizumab). Immune-related nephritis is a rare complication of checkpoint inhibitors therapy, with the most commonly reported underlying pathology being acute tubulo-interstitial nephritis. The most common presentation of immune-related nephritis includes asymptomatic increase in creatinine levels. In the absence of alternative etiologies (e.g. prerenal and postrenal causes, concomitant medications), immune-related nephritis is defined as a renal dysfunction requiring steroids treatment and/or confirmed by biopsy. Healthcare professionals are advised to monitor patients for changes in renal function and to withhold Tecentriq^® for moderate (Grade 2) immune-related nephritis, and permanently discontinue Tecentriq^® for severe nephritis (Grade 3 and 4). It is also recommended to administer corticosteroids and/or additional immunosuppressive agents as clinically indicated. Roche Singapore Pte Ltd is working with HSA to update the Singapore package insert for Tecentriq^® to include the risk of immune-related nephritis. Please refer to the letter for details.